In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin

被引:26
|
作者
Gould, IM
Milne, K
机构
[1] Department of Medical Microbiology, Aberdeen Royal Hospital NHS Trust, Aberdeen Royal Infirmary
关键词
D O I
10.1093/jac/39.1.53
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Six isolates each of Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Citrobacter spp., Serratia spp., Acinetobacter spp. and Enterobacter spp. (total 60 strains) were studied against the combination of piperacillin/tazobactam plus gentamicin or ciprofloxacin at physiological concentrations by the microtitre chequerboard method incorporating simultaneous time-kill curves. Tazobactam was fixed at 4 mg/L. Gentamicin plus piperacillin/tazobactam was a synergic combination against 28 strains at 2 h, 51 at 5 h and 54 at 24 h as assessed by time-kilt curves and synergic or additive (FBC index less than or equal to 1) against all 60 strains at 24 h by chequerboards. The corresponding figures for ciprofloxacin plus piperacillin/tazobactam were seven, 26, 52 and 58 respectively. Antagonism (FBC index greater than or equal to 4) was demonstrated for one strain to each combination at 24 h. There were no significant differences between FIC indices and FBC indices for each antibiotic combination. Gentamicin plus piperacillin/tazobactam gave greater than or equal to 3 log kill for 47 strains by 2 h, 56 by 5 h and 59 by 24 h. Ciprofloxacin plus piperacillin/tazobactam gave greater than or equal to 3 log kill for 22 strains by 2 h, 36 by 5 h and 56 by 24 h. In conclusion both antibiotic combinations at physiological concentrations were synergic or additive at 24 h for the majority of strains tested although notably gentamicin plus piperacillin/tazobactam gave faster kill. Antagonism was rarely seen. Both combinations are likely to prove beneficial for treatment of serious infections.
引用
收藏
页码:53 / 61
页数:9
相关论文
共 50 条
  • [21] PIPERACILLIN AND TAZOBACTAM VERSUS CLINDAMYCIN AND GENTAMICIN IN THE TREATMENT OF HOSPITALIZED WOMEN WITH PELVIC INFECTION
    SWEET, RL
    ROY, S
    FARO, S
    OBRIEN, WF
    SANFILIPPO, JS
    SEIDLIN, M
    MCGREGOR, JA
    PASTOREK, JA
    AUGER, P
    SUMMITT, RL
    MURRAY, G
    SANDS, M
    BROOKER, DC
    BHATIA, NN
    MONIF, GRG
    MITCHELL, J
    OBSTETRICS AND GYNECOLOGY, 1994, 83 (02): : 280 - 286
  • [22] COMPARATIVE IN-VITRO ACTIVITY OF PIPERACILLIN TAZOBACTAM AGAINST RECENT CLINICAL ISOLATES, A DUTCH NATIONAL MULTICENTER STUDY
    STOBBERINGH, EE
    MACLAREN, DM
    SCHMITZ, PIM
    DIRKSGO, SIS
    DANKERT, J
    LIGTVOET, EEJ
    LICHTENDAHLBERNARDS, AT
    HORREVORTS, AM
    THEWESSEN, EAPM
    BANFFER, JRJ
    WAGENVOORT, JHT
    HENDRIKS, WDH
    BRIMICOMBE, RW
    LIM, BT
    VISSER, MR
    VANKLINGEREN, B
    VANKREGTEN, E
    DEJONG, J
    SCHREUDER, H
    SABBE, LJM
    WINTERMANS, RGF
    DIEPERSLOOT, RJA
    SONDERKAMP, HJA
    VANDIJKE, BF
    FABIUS, GTJ
    DAVIES, BI
    HOOGKAMPKORSTANJE, JAA
    DEJONG, A
    SEVERIN, WPJ
    DEGENER, JE
    MANSON, WL
    VERBRUGH, H
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 34 (05) : 777 - 783
  • [23] Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam
    Kim, MK
    Xuan, DW
    Quintiliani, R
    Nightingale, CH
    Nicolau, DP
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (02) : 259 - 267
  • [24] GENTAMICIN IN-VITRO EVALUATION
    CAMPOSFI.J
    SOTOSANC.E
    SIGALADE.C
    RUIZSANC.A
    MEDICINA-REVISTA MEXICANA, 1974, 54 (1188): : 433 - 437
  • [25] PIPERACILLIN TAZOBACTAM PLUS GENTAMICIN AS EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCY
    KELSEY, SM
    WEINHARDT, B
    POCOCK, CE
    SHAW, E
    NEWLAND, AC
    JOURNAL OF CHEMOTHERAPY, 1992, 4 (05) : 281 - 285
  • [26] Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital
    Plastsouka, E
    Zissis, NP
    Constantoulaki, S
    Paniara, O
    JOURNAL OF CHEMOTHERAPY, 1997, 9 (05) : 336 - 340
  • [27] The use of piperacillin-tazobactam coated tympanostomy tubes against ciprofloxacin-resistant Pseudomonas biofilm formation: An in vitro study
    Jang, Chul Ho
    Park, Haekyun
    Cho, Yong Bum
    Choi, Cheol Hee
    Park, Il Yong
    INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2009, 73 (02) : 295 - 299
  • [28] Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: A data analysis
    Frei, Christopher R.
    Hampton, Shanna L.
    Burgess, David S.
    CLINICAL THERAPEUTICS, 2006, 28 (07) : 1035 - 1040
  • [29] A pharmacokinetic and pharmacodynamic analysis of continuously infused piperacillin/tazobactam in critically ill trauma patients
    Silinskic, Kevin M.
    Domonoske, Brad
    Cocanour, Christine S.
    CRITICAL CARE MEDICINE, 2007, 35 (12) : A115 - A115
  • [30] Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam
    Cormio, L
    Berardi, B
    Callea, A
    Fiorentino, N
    Sblendorio, D
    Zizzi, V
    Traficante, A
    BJU INTERNATIONAL, 2002, 90 (07) : 700 - 702